Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.

Macpherson IR, Spiliopoulou P, Rafii S, Saggese M, Baird RD, Garcia-Corbacho J, Italiano A, Bonneterre J, Campone M, Cresti N, Posner J, Takeda Y, Arimura A, Spicer J.

Breast Cancer Res. 2019 Dec 31;22(1):1. doi: 10.1186/s13058-019-1178-0.

2.

Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy.

Tzolos E, Adamson PD, Hall PS, Macpherson IR, Oikonomidou O, MacLean M, Lewis SC, McVicars H, Newby DE, Mills NL, Lang NN, Henriksen PA.

Clin Oncol (R Coll Radiol). 2019 Dec 5. pii: S0936-6555(19)30496-0. doi: 10.1016/j.clon.2019.11.008. [Epub ahead of print]

3.

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.

Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P.

Lancet Oncol. 2019 Aug;20(8):1124-1135. doi: 10.1016/S1470-2045(19)30328-6. Epub 2019 Jun 27.

PMID:
31257177
4.

Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels.

Novo D, Heath N, Mitchell L, Caligiuri G, MacFarlane A, Reijmer D, Charlton L, Knight J, Calka M, McGhee E, Dornier E, Sumpton D, Mason S, Echard A, Klinkert K, Secklehner J, Kruiswijk F, Vousden K, Macpherson IR, Blyth K, Bailey P, Yin H, Carlin LM, Morton J, Zanivan S, Norman JC.

Nat Commun. 2018 Nov 29;9(1):5069. doi: 10.1038/s41467-018-07339-y.

5.

The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review.

Copson E, Shaaban AM, Maishman T, Moseley PM, McKenzie H, Bradbury J, Borley A, Brzezinska M, Chan SYT, Ching J, Cutress RI, Danial I, Dall B, Kerin M, Lowery AJ, Macpherson IR, Romics L, Sawyer E, Sharmat N, Sircar T, Vidya R, Pan Y, Rea D, Jones L, Eccles DM, Berditchevski F.

Breast. 2018 Dec;42:133-141. doi: 10.1016/j.breast.2018.09.003. Epub 2018 Sep 15.

PMID:
30278369
6.

Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA).

Convertino M, Church TR, Olsen GW, Liu Y, Doyle E, Elcombe CR, Barnett AL, Samuel LM, MacPherson IR, Evans TRJ.

Toxicol Sci. 2018 May 1;163(1):293-306. doi: 10.1093/toxsci/kfy035.

7.

Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells.

Dornier E, Rabas N, Mitchell L, Novo D, Dhayade S, Marco S, Mackay G, Sumpton D, Pallares M, Nixon C, Blyth K, Macpherson IR, Rainero E, Norman JC.

Nat Commun. 2017 Dec 21;8(1):2255. doi: 10.1038/s41467-017-02101-2.

8.

Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial.

Hall PS, Smith A, Hulme C, Vargas-Palacios A, Makris A, Hughes-Davies L, Dunn JA, Bartlett JMS, Cameron DA, Marshall A, Campbell A, Macpherson IR, Dan Rea, Francis A, Earl H, Morgan A, Stein RC, McCabe C; OPTIMA Trial Management Group.

Value Health. 2017 Dec;20(10):1311-1318. doi: 10.1016/j.jval.2017.04.021. Epub 2017 Jul 11.

9.

Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice.

Cain H, Macpherson IR, Beresford M, Pinder SE, Pong J, Dixon JM.

Clin Oncol (R Coll Radiol). 2017 Oct;29(10):642-652. doi: 10.1016/j.clon.2017.06.003. Epub 2017 Jun 29. Review.

10.

Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity.

Hernandez-Fernaud JR, Ruengeler E, Casazza A, Neilson LJ, Pulleine E, Santi A, Ismail S, Lilla S, Dhayade S, MacPherson IR, McNeish I, Ennis D, Ali H, Kugeratski FG, Al Khamici H, van den Biggelaar M, van den Berghe PV, Cloix C, McDonald L, Millan D, Hoyle A, Kuchnio A, Carmeliet P, Valenzuela SM, Blyth K, Yin H, Mazzone M, Norman JC, Zanivan S.

Nat Commun. 2017 Feb 15;8:14206. doi: 10.1038/ncomms14206.

11.

Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.

Kristeleit H, Parton M, Beresford M, Macpherson IR, Sharma R, Lazarus L, Kelleher M.

Target Oncol. 2016 Oct;11(5):579-591. Review.

12.

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.

Bartlett JM, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, Sobol MS, Hall PS, Poole CJ, Cameron DA, Earl HM, Rea DW, Macpherson IR, Canney P, Francis A, McCabe C, Pinder SE, Hughes-Davies L, Makris A, Stein RC; OPTIMA TMG.

J Natl Cancer Inst. 2016 Apr 29;108(9). pii: djw050. doi: 10.1093/jnci/djw050. Print 2016 Sep.

13.

A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer.

Marshall-McKenna R, Morrison A, Stirling L, Hutchison C, Rice AM, Hewitt C, Paul L, Rodger M, Macpherson IR, McCartney E.

Support Care Cancer. 2016 Apr;24(4):1821-9. doi: 10.1007/s00520-015-2967-3. Epub 2015 Oct 8.

PMID:
26446702
14.

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.

Palmieri C, Macpherson IR, Yan K, Ades F, Riddle P, Ahmed R, Owadally W, Stanley B, Shah D, Gojis O, Januszewski A, Lewanski C, Asher R, Lythgoe D, de Azambuja E, Beresford M, Howell SJ.

Oncotarget. 2016 Mar 15;7(11):13209-20. doi: 10.18632/oncotarget.4801.

15.

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

Argilés G, Saunders MP, Rivera F, Sobrero A, Benson A 3rd, Guillén Ponce C, Cascinu S, Van Cutsem E, Macpherson IR, Strumberg D, Köhne CH, Zalcberg J, Wagner A, Luigi Garosi V, Grunert J, Tabernero J, Ciardiello F.

Eur J Cancer. 2015 May;51(8):942-9. doi: 10.1016/j.ejca.2015.02.013. Epub 2015 Mar 25.

PMID:
25818084
16.

Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.

Macpherson IR, Bray C, Hopkins C, Hannon RA, Lewsley LA, Ritchie DM, Canney P.

Clin Breast Cancer. 2015 Apr;15(2):117-27. doi: 10.1016/j.clbc.2014.09.009. Epub 2014 Oct 2.

PMID:
25454689
17.

A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.

Hickish T, Cassidy J, Propper D, Chau I, Falk S, Ford H, Iveson T, Braun M, Potter V, Macpherson IR, Finnigan H, Lee C, Jones H, Harrison M.

Eur J Cancer. 2014 Dec;50(18):3136-44. doi: 10.1016/j.ejca.2014.08.008. Epub 2014 Oct 28.

PMID:
25441408
18.

CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer.

Macpherson IR, Rainero E, Mitchell LE, van den Berghe PV, Speirs C, Dozynkiewicz MA, Chaudhary S, Kalna G, Edwards J, Timpson P, Norman JC.

J Cell Sci. 2014 Sep 15;127(Pt 18):3893-901. doi: 10.1242/jcs.135947. Epub 2014 Jul 11.

19.

Response to: 'Letter to the editor, European Journal of Cancer', commenting on 'Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma'.

Shepherd ST, Macpherson IR, White JD, Mark PB.

Eur J Cancer. 2014 Aug;50(12):2178-9. doi: 10.1016/j.ejca.2014.04.027. Epub 2014 May 28. No abstract available.

PMID:
24878064
20.

Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.

Shepherd ST, Gillen G, Morrison P, Forte C, Macpherson IR, White JD, Mark PB.

Eur J Cancer. 2014 Mar;50(5):944-52. doi: 10.1016/j.ejca.2013.12.021. Epub 2014 Jan 17.

PMID:
24445148
21.

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.

Anthoney DA, Naik J, Macpherson IR, Crawford D, Hartley JM, Hartley JA, Saito T, Abe M, Jones K, Miwa M, Twelves C, Evans TR.

BMC Cancer. 2012 Nov 21;12:536. doi: 10.1186/1471-2407-12-536.

22.

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.

Macpherson IR, Poondru S, Simon GR, Gedrich R, Brock K, Hopkins CA, Stewart K, Stephens A, Evans TR.

Eur J Cancer. 2013 Mar;49(4):782-9. doi: 10.1016/j.ejca.2012.09.036. Epub 2012 Oct 22.

PMID:
23099006
23.

Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane.

Macpherson IR, Lindsay C, Canney P.

Breast Cancer (Dove Med Press). 2010 Oct 14;2:59-70. doi: 10.2147/BCTT.S11835. Review.

24.

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.

Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR.

Clin Cancer Res. 2009 Oct 1;15(19):6232-40. doi: 10.1158/1078-0432.CCR-09-0224. Epub 2009 Sep 29.

25.

Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.

Lindsay CR, MacPherson IR, Cassidy J.

Future Oncol. 2009 May;5(4):421-32. doi: 10.2217/fon.09.18. Review.

PMID:
19450171
26.

Recombinant human epoetin beta in the treatment of chemotherapy-related anemia.

Macpherson IR, Lindsay CR, Reed NS.

Ther Clin Risk Manag. 2009 Feb;5(1):261-70. Epub 2009 Mar 26.

27.
28.

p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism.

Macpherson IR, Hooper S, Serrels A, McGarry L, Ozanne BW, Harrington K, Frame MC, Sahai E, Brunton VG.

Oncogene. 2007 Aug 9;26(36):5214-28. Epub 2007 Mar 5.

PMID:
17334396
29.

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.

Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG.

Mol Cancer Ther. 2006 Dec;5(12):3014-22. Epub 2006 Dec 5.

30.

Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry.

Brunton VG, MacPherson IR, Frame MC.

Biochim Biophys Acta. 2004 Jul 5;1692(2-3):121-44. Review.

31.

Auto-immune neutropenia occurring in association with malignant melanoma.

White JD, MacPherson IR, Evans TR.

Oncol Rep. 2003 Jan-Feb;10(1):249-51.

PMID:
12469177

Supplemental Content

Loading ...
Support Center